Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapastinel as adjunctive therapy in MDD
NCT02932943Phase 3Completed
- Sponsor
- Allergan
- Start
- Oct 2016
- Primary completion
- Sep 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Rapastinel 450 mg with Placebo (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale at 3 weeks. Started Oct 2016; status: completed.
02
Drugs
rapastinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02932943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932943.